Sym006 (undisclosed bacterial target) is a recombinant polyclonal antibody being developed against an undisclosed bacterial pathogen. The program is fully funded by Meiji Seika Kaisha Pharma.

Status
Sym006 is currently in the lead discovery phase.

Infectious Disease
Current Partners